GlassScriptPhysician profile
David K Jeong
NPI 1912023565
$68,385.88
in general payments reported to CMS, 2019-2025
29 companies · $6,697 in 2025
The $6,697 reported for 2025 was more than what 85% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $40.95 · 2020: $1,353 · 2021: $1,523 · 2022: $4,125 · 2023: $21K · 2024: $34K · 2025: $6,697.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $38K · Food and Beverage: $8,890 · Honoraria: $6,253 · Consulting Fee: $5,370 · Travel and Lodging: $2,569 · Education: $63.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $38,200.00 |
| Food and Beverage | $8,889.75 |
| Honoraria | $6,252.50 |
| Consulting Fee | $5,369.50 |
| Travel and Lodging | $2,568.83 |
| Education | $63.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $38,015.41 | 2021-2025 | Tezspire, Airsupra, Fasenra |
| Blueprint Medicines Corporation | $10,333.27 | 2022-2025 | Ayvakit |
| Novartis Pharmaceuticals Corporation | $7,170.97 | 2022-2025 | |
| Amgen INC. | $4,425.17 | 2022-2025 | Tezspire |
| Genzyme Corporation | $3,050.12 | 2020-2025 | |
| Biocryst US Sales Co., LLC | $983.23 | 2023-2025 | Orladeyo |
| Glaxosmithkline, LLC. | $818.84 | 2022-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Csl Behring | $739.79 | 2022-2025 | Hizentra, Haegarda |
| Takeda Pharmaceuticals U.S.A., INC. | $647.37 | 2022-2025 | Takhzyro, Cuvitru, Hyqvia |
| Regeneron Healthcare Solutions, INC. | $610.33 | 2022-2025 | Dupixent |
| Pharming Healthcare, INC. | $380.60 | 2022-2025 | Ruconest |
| Grifols USA, LLC | $233.19 | 2022-2025 | Xembify, Prolastin-C Liquid |
| Pfizer INC. | $197.17 | 2022-2024 | |
| Genentech USA, INC. | $180.64 | 2019-2025 | Xolair |
| Kaleo, INC. | $98.83 | 2023 | Auvi-Q |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ars Pharmaceuticals Operations, INC. | $85.81 | 2025 | Neffy |
| Abbvie INC. | $76.02 | 2024 | |
| Adma Biomanufacturing LLC | $63.25 | 2024-2025 | |
| Alk-Abello, INC | $61.79 | 2022-2024 | Grastek, Odactra, Ragwitek |
| Dermavant Sciences, INC. | $48.31 | 2024 | Vtama |
| Ionis Pharmaceuticals, INC. | $25.00 | 2025 | |
| Aerin Medical INC. | $24.13 | 2024 | |
| Lilly USA, LLC | $23.95 | 2024 | Ebglyss |
| Phadia US INC. | $20.67 | 2023 | Immunocap |
| Cycle Pharmaceuticals INC | $19.98 | 2024 | Sajazir |
| Teva Pharmaceuticals USA, INC. | $19.85 | 2023 | Airduo Digihaler |
| Merck Sharp & Dohme LLC | $18.78 | 2023 | |
| Hikma Pharmaceuticals USA | $13.41 | 2023 | Ryaltris |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Jeong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.